Wave Life Sciences Ltd. (NASDAQ: WVE) will release its second quarter 2026 financial results on July 30, 2026. The clinical-stage biotechnology company will host a live webcast and conference call at 8:30 a.m. ET to review the quarterly performance and provide broader business updates. This announcement marks the next scheduled disclosure for the Cambridge-based firm, which is focused on developing RNA medicines for rare and common disorders.

The live event will be accessible through the "Investor Events" section of Wave Life Sciences’ investor relations website. Analysts planning to participate in the question-and-answer portion of the call may join via a dedicated audio-conferencing link provided by the company. Following the live broadcast, an archived version of the webcast will remain available on the corporate website for subsequent review.

Pipeline and Platform Overview

Wave Life Sciences utilizes its PRISM platform, which combines multiple modalities, chemistry innovation, and insights into human genetics. The company’s toolkit includes RNA interference (SpiNA) and RNA editing (AIMers) technologies designed to address specific disease biology.

The current pipeline focuses on several key therapeutic areas:

In addition to these primary programs, Wave Life Sciences maintains clinical initiatives in Duchenne muscular dystrophy and Huntington’s disease. The company also operates several preclinical programs leveraging its versatile RNA medicines platform.

Investor and Media Contact

Investors seeking further information or wishing to participate in the upcoming call may contact James Salierno, Director of Investor Relations, at +1 617-949-4043 or via email at InvestorRelations@wavelifesci.com . For media inquiries, Katie Sullivan, Senior Director of Corporate Communications, is available at +1 617-949-2936 or MediaRelations@wavelifesci.com . Kate Rausch, VP of Corporate Affairs and Investor Relations, serves as the primary point of contact for general corporate affairs at +1 617-949-4827.

Wave Life Sciences Ltd. has obtained the requisite shareholder approval to proceed with its proposed redomiciliation to the United States through a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore. The company filed an application with the Singapore High Court to approve the Scheme of Arrangement, which remains subject to judicial sanction. The hearing is scheduled for July 14, 2026, at 2:30 pm at Chamber 2A of the Supreme Court of Singapore.

The application, filed as HC/SUM 2058/2026 in HC/OA 434/2026 on July 1, 2026, outlines the statutory procedure for changing the parent company from a Singapore company to a Delaware corporation. The Singapore Court has directed that any affidavits in response to the application must be submitted by 4:00 pm on July 8, 2026. Additionally, written submissions and bundles of authorities must be filed and tendered to the court by 4:00 pm on July 10, 2026.

Key Dates and Deadlines

The following timeline has been established by the Singapore Court for the redomiciliation process:

Wave Life Sciences stated that materials filed with the application and the court's directions will be made available in the Corporate Governance section of its Investor Relations website. The company cautioned that the completion of the redomiciliation is subject to satisfying closing conditions and receiving necessary approvals within the expected timeframe.

About Wave Life Sciences

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines. Its pipeline includes programs for obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), alongside clinical programs in Duchenne muscular dystrophy and Huntington’s disease. The company is headquartered in Cambridge, MA.